StockNews.AI
AMD
StockNews.AI
70 days

Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Data at Clinical Trials at the Summit and MaculArt

1. Ashvattha presents Phase 2 data on migaldendranib for wet AMD. 2. Migaldendranib offers a patient-friendly alternative to injection treatments. 3. New therapy aims to normalize VEGF expression for better outcomes. 4. Presentations scheduled for late June and early July 2025. 5. Ashvattha aims to redefine precision medicine in ophthalmology.

5m saved
Insight
Article

FAQ

Why Bullish?

Advancements in AMD treatment could enhance AMD market, positively affecting AMD stock.

How important is it?

The development of novel therapies in AMD may influence AMD's future market position.

Why Long Term?

If successful, migaldendranib could shift AMD treatment landscape over several years.

Related Companies

NVDAINTCTSM
June 10, 2025 08:01 ET  | Source: Ashvattha Therapeutics Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company is exploring new technology to normalize VEGF expression, potentially enhancing both safety and efficacy of treatments for retinal and other diseases REDWOOD CITY, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced it will present at Clinical Trials at the Summit, June 21, 2025, in Las Vegas, and MaculArt, June 29 – July 1, 2025 in Paris. Ashvattha’s presentations will focus on previously reported Phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), which could offer a more convenient alternative to current injection-based treatments. Migaldendranib has a novel mechanism of action involving normalization of vascular endothelial growth factor (VEGF) expression in activated macrophage, microglia and retinal pigment epithelial cells. Clinical Trials at the Summit: Presentation Title: Subcutaneous Delivery of Migaldendranib: Twenty-four Week Results of a Phase 2 Study in DME and AMDPresentation Date/Time: Saturday, June 21, 2025; 9:01-9:05am PDTSession Type: PresentationPresenter: David Boyer, MD, Senior Partner, Retina-Vitreous Associates Medical Group and Adjunct Clinical Professor of Ophthalmology, University of Southern California/Keck School of MedicinePresentation Title: Emerging Technology: A Targeted, Novel, Nano-medicine that Normalizes VEGF ExpressionPresentation Date/Time: Saturday, June 21, 2025; 8:57-9:01am PDTSession Type: PresentationPresenter: Susan Schneider, MD, Retinal Ophthalmologist MaculArt: Presentation Title: Subcutaneous Migaldendranib (MGB) for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Interim Results of Chronic Dosing Phase 2 StudyPresentation Date/Time: Sunday, June 29, 2025; 2:16-2:24pm CESTSession Type: PresentationPresenter: Michael Singer, MD, Clinical Professor of Ophthalmology, University of Texas Health Science Center San Antonio and Director of Clinical Research, Medical Center Ophthalmology San Antonio About Ashvattha Therapeutics Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care in ophthalmology. Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: www.avttx.com MediaICR HealthcareAshvatthaPR@icrhealthcare.com Investor RelationsAman Patel, CFA & Adanna G. Alexander, PhDAshvatthaIR@icrhealthcare.com

Related News